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Background:  Decreases in peroxisome proliferators-activated receptor gamma ( PPAR-γ) expression in 
subcutaneous adipose tissue may be important in the pathogenesis of lipoatrophy. Despite this, rosiglitazone (RSG), 
a PPAR-γ agonist, has not been shown to increase limb fat in lipoatrophic HIV-infected patients. 
Methods:  We completed a sub-study of a randomized, placebo-controlled, 48-week trial examining the effect of 
RSG 4 mg twice daily on limb fat in 100 HIV-infected adults with lipoatrophy. We examined changes in mRNA 
expression in subcutaneous fat biopsies, performed at weeks 0, 2, and 48. RNA was extracted and real-time RT-PCR 
performed for mitochondrial and lipid metabolism genes, with results presented relative to β-actin expression, which 
did not change. Non-parametric analyses were applied. 
Results:  We recruited 44 men (RSG n = 21, placebo n = 23) to this sub-study of which 21 were receiving the 
thymidine analogues (tNRTI) zidovudine (AZT) (n = 3) or stavudine (d4T) (n = 18) at baseline. Although groups 
were matched for baseline PPAR-γ expression (p = 0.8), limb fat was lower in the RSG group (1.9 kg vs 2.3kg). 
Mitochondrial-encoded cytochrome-b expression was significantly lower in those treated with tNRTI (median 2.53 
[IQR 4.45] vs 6.04 [4.54] for the no-tNRTI group, p = 0.001). At week 2, only those randomized to RSG in the no-
tNRTI group experienced a significant rise in PPAR-γ expression (p = 0.046). Similar significant increases in 
PPAR-γ co-activator 1 (PGC-1) expression were also observed in the RSG no-tNRTI group. At week 48, PPAR-γ 
expression was significantly higher only in the no-tNRTI group, regardless of randomized treatment allocation (p = 
0.04), with RSG having no effect in the tNRTI group (see the table). No significant correlations were observed 
between changes in PPAR-γ or PGC-1 expression and change in limb fat. 
  
                                                  PPARγ 
   Week 2  Week 48 
   tNRTI  no tNRTI  tNRTI  no tNRTI 
RSG  12 [99]  68 [56]  –22 [154]  87 [166] 
Placebo  2 [97]  7 [173]  –32 [131]  74 [181] 
                                                  PGC-1 
RSG  13 [69]  149 [341]  29 [63]  672 [976] 
Placebo  35 [131]  107 [181]  119 [118]  313 [220] 
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